Navigation Links
Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
Date:11/8/2010

Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant... -- ABBOTT PARK, Ill., Nov. 8, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Infection Control, Medical Pharmaceuticals, Pharmaceuticals, Joint Ventures, Children-related News, Domestic Policy, Corporate Social Responsibility Click to view news release full screen  

Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa

 

ABBOTT PARK, Ill., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and the Clinton Health Access Initiative (CHAI) have joined forces to provide HIV testing to infants in all countries working in partnership with the CHAI.  A key focus of this cooperation will be sub-Saharan Africa, which the World Health Organization estimates to account for 90 percent of global HIV infections in children.

Under terms of the agreement, Abbott will supply its RealTime HIV-1 Qualitative test kits to healthcare facilities.  The test is currently available for research use only and is expected to be CE marked (Conformite Europeene) by January 2011.  Abbott will also offer the capability to collect and process samples using dried blood spots (DBS).  The use of DBS for specimen collection eliminates the need for refrigeration of specimens.

In addition to the supply of HIV tests and DBS sample collection for research use, Abbott is collaborating with CHAI to develop a "turn-key" laboratory solution, including training protocols on instruments that will be used to establish fully functioning molecular diagnostic laboratories in regions where such facilities do not currently exist.

"We're pleased to be collaborating with the CHAI in its proactive outreach effort to test infants in developing nations for HIV," said Stafford O'Kelly, head of Abbott's molecular diagnostics business.  "Accurate and accessible HIV testing, particularly for diagnosis of HIV/AIDS in infants less than 18 months of age, is essential for optimal management and treatment of the disease."

About Abbott Molecular Abbott Molecular, abbottmolecular.com, is an emerging leader in molecular diagnostics - the analysis of DNA, RNA, and proteins at the molecular level.  Abbott Molecular's instruments and assays are used for early detection and diagnosis of disease, to influence the selection of appropriate therapies and as an aid in monitoring disease progression.

About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
2. Abbott Again Recognized for Environmental Initiatives in Illinois
3. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
4. Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S.
5. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
6. Abbott Named One of the Top Employers in the Biotech and Pharmaceutical Industry by Science Magazine
7. Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution
8. Abbotts XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
9. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
10. Abbotts Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
11. The Deal Names Abbott Top Dealmaker for Third Consecutive Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization GenCure, ... at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood donations ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB since ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... Bill ... management industry in the coastal communities. After Tina Howe joined the team, the Bill ... happy employees, honest services at affordable rates, and giving back to the San Diego ...
Breaking Medicine News(10 mins):